ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
Dow Jones
39.112,16
-0,76%
Euro vs US Dollar
1,07099
0,01%
Bitcoin
61.695,75
-0,17%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Karuna Therapeutics Inc (KRTX)

  7. Karuna Therapeutics Inc (KRTX) News

KRTX

Karuna Therapeutics (KRTX)

Karuna Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:KRTX
DatumZeitQuelleÜberschriftSymbolFirma
11/03/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
08/03/202423h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
01/03/202412h02Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
01/03/202412h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRTXKaruna Therapeutics Inc
22/02/202412h39Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KRTXKaruna Therapeutics Inc
22/02/202412h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRTXKaruna Therapeutics Inc
22/02/202412h30Business WireKaruna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business UpdateNASDAQ:KRTXKaruna Therapeutics Inc
15/02/202422h53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
15/02/202422h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
15/02/202422h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
15/02/202422h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
14/02/202416h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KRTXKaruna Therapeutics Inc
12/02/202423h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
12/02/202423h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
08/02/202417h56Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
05/02/202422h12Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:KRTXKaruna Therapeutics Inc
22/01/202412h05Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:KRTXKaruna Therapeutics Inc
16/01/202422h18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRTXKaruna Therapeutics Inc
09/01/202422h34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
08/01/202422h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
08/01/202416h06PR Newswire (US)Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmNASDAQ:KRTXKaruna Therapeutics Inc
29/12/202322h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202323h20Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202323h20Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202323h07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202322h28Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202322h22Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202322h12Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRTXKaruna Therapeutics Inc
22/12/202321h30PR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Karuna Therapeutics, Inc.NASDAQ:KRTXKaruna Therapeutics Inc
22/12/202317h15Dow Jones NewsTrending: Bristol Myers to Buy Karuna Therapeutics for $14 BillionNASDAQ:KRTXKaruna Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KRTX

Kürzlich von Ihnen besucht

LSE
SYM
Symphony Environmental T...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten